Skip to content

Mannkind MNKD Additional Paid-In Capital

Additional Paid-In Capital at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$1.4B+5.0%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$141.53M+5.7%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.51B+9.3%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
$686.35M+73.0%
Eli Lilly logo
Eli LillyLLY
Cytokinetics logo
CytokineticsCYTK

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's additional paid-in capital?
Mannkind (MNKD) reported additional paid-in capital of $3.15B in Q1 2026.
How has Mannkind's additional paid-in capital changed year-over-year?
Mannkind's additional paid-in capital increased by 0.8% year-over-year, from $3.13B to $3.15B.
What is the long-term trend for Mannkind's additional paid-in capital?
Over 5 years (2020 to 2025), Mannkind's additional paid-in capital has grown at a 1.9% compound annual growth rate (CAGR), from $2.87B to $3.14B.
What does additional paid-in capital mean?
This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.